



Revance Therapeutics
 Investor Relations Department
 7555 Gateway Boulevard
 Newark, CA 94560
 United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: RVNC	
Last Trade:	20.60
Trade Time:	4:00 PM ET May 23, 2017
Change:	0.25 (+1.229%)
Day Range	20.20 - 20.70
52-Week Range	12.35 - 24.30
Volume	89,319


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 18, 2017*
[Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial](#)
- May 9, 2017*
[Revance Releases First Quarter 2017 Results](#)
- May 1, 2017*
[Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis](#)
- Apr 25, 2017*
[Revance Therapeutics to Release First Quarter 2017 Financial Results Tuesday, May 9, 2017](#)
- Mar 7, 2017*
[Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar \(Frown\) Lines](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Feb 28, 2017*
[Annual Report \(10-K\)](#)
- Mar 24, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 5, 2016*
[Quarterly Report \(10-Q\)](#)